RT Magazine

The Astral 100 and Astral 150 ventilators provide continuous or intermittent ventilatory support for patients weighing more than 5 kg who require mechanical ventilation, the FDA reports. The ventilators are intended for use in home, institutional/hospital, and portable settings for both invasive and noninvasive ventilation. In a subset of Astral 100 and Astral 150 ventilators, Resmed has identified that a component (called a “supercapacitor”) may leak over time.

Population-Level Impact: The study found that the introduction of multiple respiratory biologics since 2015 is associated with immediate and sustained declines in asthma exacerbation rates among adults. Severe Disease Benefits: Patients with more severe asthma and those with elevated eosinophil counts of 450 cells/μL or higher experienced the most significant reductions in exacerbations following the approval of these therapies.

FDA Clearance: HoneyNaps received USFDA 510(k) clearance for its Somnum V3.0 software designed to analyze sleep data. Automated Classification: The Ai-based tool automatically detects and classifies obstructive, central, and mixed sleep apnea with a reported 97% agreement rate. Future Biomarkers: The company plans to integrate additional markers such as hypoxic, arousal, and ventilatory burden into future versions of the platform.

Treatment Alternative: Expanded access programs, also known as compassionate use, provide a pathway for patients with life-threatening lung diseases to access investigational medications or devices when clinical trials are not an option. Regulatory Oversight: These programs require coordination and approval from the patient’s physician, the manufacturer, an Institutional Review Board (IRB), and the Food and Drug Administration (FDA).

Immunity Loss and Surge Timing: Researchers found that the lack of seasonal respiratory infections during the pandemic led to a buildup of susceptible individuals, causing subsequent surges to occur earlier in the season. Cardiovascular Link: The study suggests that respiratory infections are key drivers for the timing of seasonal surges in cardiovascular deaths, as heart-related mortality patterns closely mirrored the shifts in infection rates.

Regulatory Milestone: The FDA has accepted the New Drug Application for AD109 and assigned a target action date of Feb 28, 2027. Novel Treatment Mechanism: AD109 is designed as a once-daily oral pill that targets the neuromuscular root cause of obstructive sleep apnea rather than relying on devices or surgery. Phase 3 Success: Clinical trials demonstrated that the medication significantly reduced the apnea-hypopnea index and improved oxygenation levels in patients with mild to severe sleep apnea.

New Regulatory Category: The Food and Drug Administration (FDA) established the ventilator waveform analysis software classification with the authorization of Syncron-E. Automated Asynchrony Detection: The software helps respiratory therapists identify ineffective efforts, which are the most frequent type of patient-ventilator mismatch and often go unrecognized during manual bedside checks.

A two-year-old Indiana child is the first in the United States to be diagnosed with Rajab Interstitial Lung Disease with brain calcifications (RILDBC-1), a rare genetic disease with only 10 known cases worldwide, according to a local Indiana news report. Rajab ILD BC-1 normally presents in infancy or early childhood with poor growth and interstitial lung disease, with some patients experiencing liver, skeletal, and renal abnormalities, and intracranial calcifications on brain imaging.

Complex Lung Retransplantation: Surgeons successfully performed a second double-lung transplant alongside liver and kidney transplants for a patient with restrictive allograft syndrome. Machine Perfusion Technology: The use of advanced machine perfusion allowed the surgical team to preserve the liver and kidney outside the body, providing the time necessary to complete the lung retransplantation.

Diagnostic Utility: A polygenic risk score combining more than 60,000 DNA variants was found to be nearly three times more predictive of idiopathic pulmonary fibrosis in high-risk individuals compared to those with lower scores. Outcome Prediction: Patients with high genetic risk scores for the disease were 23% more likely to require a lung transplant or face mortality.